Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung Bioepis Files Biosimilar Enbrel In South Korea

This article was originally published in PharmAsia News

Executive Summary

Samsung Bioepis has applied for the approval in South Korea of production and sales of SB4, its biosimilar version of Amgen Inc.’s arthritis blockbuster Enbrel (etanercept).

You may also be interested in...

Celltrion Wins Korea Approval For Roche Herceptin Biosimilar

Celltrion gains approval for its second monoclonal antibody biosimilar following a biosimilar of Johnson & Johnson’s Remicade. The approval marks the second entry of a Herceptin biosimilar and the first based on global clinical trials, but Roche believes it is adequately protected against the competition.

LG Life Obtains Korea FDA Approval To Conduct Clinical Trials For Biosimilar Following Celltrion, Hanwha

SEOUL - South Korea's LG Life Sciences became the third local pharma company to obtain Korea FDA approval to conduct clinical trials of its biosimilar, code-named LBEC0101, on the heels of clinical trial clearance for Celltrion and Hanwha Chemicals

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts